Heron Therapeutics, Inc.

Jersey City,  NJ 
United States
  • Booth: 3531


Heron’s mission is to improve patient’s lives by developing best-in-class medicines that address major unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to proven pharmacological agents.

Our product portfolio includes SUSTOL® (granisetron) extended release injection approved by the US Food and Drug Administration, as well as two products in development:  HTX-019, a polysorbate 80-free, intravenous formulation of aprepitant, and HTX-011, a long-acting formulation of bupivacaine in a fixed-dose combination with meloxicam currently being studied for the prevention of postoperative pain.


  • Pharmaceuticals